633327-22-7

Basic information

• Product Name: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE
• Synonyms: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE
• CAS NO: 633327-22-7
• Molecular Formula: C₇H₃BrF₂O
• Molecular Weight: 220.9989264
• Mol File: 633327-22-7.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 230.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.758±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE(633327-22-7)
• EPA Substance Registry System: 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE(633327-22-7)

Safety Data

• Hazardous Substances Data: 633327-22-7(Hazardous Substances Data)

Usage

General Description

5-Bromo-2,3-Difluoro-Benzaldehyde is a synthetic halogenated chemical compound predominantly used in the field of organic synthesis and pharmaceutical manufacturing. Its molecular formula is C7H3BrF2O, with bromine and fluorine as the halogen elements. As an aromatic compound, it is characterized by a Benzaldehyde group which contains a formyl group and a benzene ring. 5-BROMO-2,3-DIFLUORO-BENZALDEHYDE often appears as a clear, colorless liquid and has a strong, pungent smell common to aldehydes. Given its reactivity, it is primarily used as a chemical intermediate or building block in the synthesis of more complex molecules. Handling and storage of 5-Bromo-2,3-Difluoro-Benzaldehyde should be done with caution due to its reactive nature.

Upstream product

• 348-61-8 1-bromo-3,4-difluorobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 633327-21-6 5-bromo-2,3-difluoro-4-trimethylsilanylbenzaldehyde 
• 2646-91-5 2,3-difluorobenzaldehyde 

Downstream Products

• 633327-23-8 3,4-difluoro-5-formylbenzonitrile 
• 887585-71-9 (5-bromo-2,3-difluorophenyl)methanol 
• 1365889-33-3 (E)-5-bromo-2,3-difluorobenzaldehyde O-methyl oxime 
• 445303-65-1 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1805422-92-7 5-bromo-1-(difluoromethyl)-2,3-difluorobenzene 
• 633327-24-9 7-fluoro-1H-indazole-5-carbonitrile 
• 1445796-37-1 C₁₂H₁₃F₂NO₃ 
• 1445796-44-0 C₇H₆F₃N 
• 1445796-43-9 C₁₂H₁₄F₃NO₂ 
• 1445796-42-8 C₁₂H₁₅F₂NO₃ 
• 1445796-41-7 C₁₄H₁₇F₂NO₄ 
• 1445796-40-6 C₉H₇BrF₂O₂ 
• 1445796-39-3 C₇H₅F₄N 
• 1445796-38-2 C₁₂H₁₃F₄NO₂ 

Relevant articles and documents

Liquid crystal compound containing dibenzothipheno oxygen-containing heterocycles and application thereof featuring high dielectric constant, high clearing point, high refractive index, high K value, etc., and suitable for displays used in VA, ECB, PALC, FFS or IPS mode

The present invention belongs to the field of liquid crystal compound materials, and relates to a liquid crystal compound containing dibenzothieno oxygen-containing heterocycles and its applications. The chemical structural formula is shown as the following formula I. The liquid crystal compound provided by the present invention and the liquid crystal composition containing the compound have the properties of high dielectric constant, high clearing point, high refractive index, high K value, etc., and is suitable for displays used in VA, ECB, PALC, FFS or IPS mode.

Cyclic aminopyrimidine derivative and activity and application thereof for inhibiting kinase (by machine translation)

The cyclic aminopyrimidine derivative has the structure of a general formula (I), a pharmaceutically acceptable salt, ester or solvate thereof, can inhibit the activity of kinases, is a plurality of kinase inhibitors, can be widely applied to treatment of cancers, and has a huge clinical application prospect. General Formula (I). (by machine translation)

Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold

Effective delivery of therapeutic drugs into the human brain is one of the most challenging tasks in central nervous system drug development because of the blood-brain barrier (BBB). To overcome the BBB, both passive permeability and efflux transporter liability of a compound must be addressed. Herein, we report our optimization related to BBB penetration of neuronal nitric oxide synthase (nNOS) inhibitors toward the development of new drugs for neurodegenerative diseases. Various approaches, including enhancing lipophilicity and rigidity of new inhibitors and modulating the pKa of amino groups, have been employed. In addition to determining inhibitor potency and selectivity, crystal structures of most newly designed compounds complexed to various nitric oxide synthase isoforms have been determined. We have discovered a new analogue (21), which exhibits not only excellent potency (Ki 30 nM) in nNOS inhibition but also a significantly low P-glycoprotein and breast-cancer-resistant protein substrate liability as indicated by an efflux ratio of 0.8 in the Caco-2 bidirectional assay.